Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12474868 | 1.00 | SLC6A4 (0.61) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL2608864 | 0.85 | CA1 (0.62) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL29127931 | 0.82 | CA1 (0.55) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL29127933 | 0.82 | CA1 (0.55) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL15831104 | 0.81 | CA1 (0.68) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL7971847 | 0.81 | CA1 (0.58) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL7971840 | 0.81 | CA1 (0.58) | SLC6A4CA1CA2IDO1AGXT | |
| SCHEMBL18580296 | 0.80 | TAAR1 (0.68) | SLC6A4IDO1AGXTMAOBTAAR1 | |
| SCHEMBL18580298 | 0.80 | TAAR1 (0.68) | SLC6A4IDO1AGXTMAOBTAAR1 | |
| SCHEMBL34413 | 0.80 | IDO1 (0.67) | CA1CA2IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045860-A1 | SMALL MOLECULE INHIBITORS FOR TREATING PARASITIC INFECTIONS | NEW YORK UNIVERSITY (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012112568-A1 | SMALL MOLECULE INHIBITORS FOR TREATING PARASITIC INFECTIONS | THE BROAD INSTITUTE, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045860-A1 | SMALL MOLECULE INHIBITORS FOR TREATING PARASITIC INFECTIONS | CYP51A1, GDI1, GDI2 | SLC6A4 3252/4885CA1 3390/4885CA2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.